Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is set to announce third quarter earning results on Wednesday 28th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, VNDA to report 3Q20 income of $ 0.09 per share.
For the full year, analysts anticipate top line of $ 251.05 million, while looking forward to income of $ 0.37 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 240.00 million ~ $ 260.00 million
Click Here For More Historical Outlooks Of Vanda Pharmaceuticals Inc.
Previous Quarter Performance
Vanda Pharmaceuticals Inc. disclosed income for the second quarter of $ 0.16 per share, from the revenue of $ 62.21 million. Street analysts expected $ 61.95 million. The top line results outshined analysts by $ 0.26 million or 0.42 percent.
Stock Performance
Shares of Vanda Pharmaceuticals Inc. traded up $ 0.16 or 1.53 percent on Tuesday, reaching $ 10.59 with volume of 757.90 thousand shares. Vanda Pharmaceuticals Inc. has traded high as $ 10.66 and has cracked $ 10.26 on the downward trend
According to the previous trading day, closing price of $ 10.59, representing a 46.49 % increase from the 52 week low of $ 7.12 and a 41.57 % decrease over the 52 week high of $ 17.85.
The company has a market capital of $ 578.76 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Vanda Pharmaceuticals Inc. will be hosting a conference call at 4:30 PM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.vandapharmaceuticals.com
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The companys marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
